Small Lymphocytic Lymphoma

CLINICAL_TRIALS withdrawal · 2025-07-03

Clinical Trial Update: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL [Phase 1]

The Phase 1 study of BMF-219, Biomea Fusion's covalent menin inhibitor, in adults with AML, ALL, DLBCL, multiple myeloma, and CLL/SLL has be…

CLINICAL_TRIALS withdrawal · 2025-06-05

Clinical Trial Update: A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

A Phase 2 study investigating the sequencing of pirtobrutinib after progression on first-line acalabrutinib in adults with chronic lymphocyt…

CLINICAL_TRIALS withdrawal · 2025-05-16

Clinical Trial Update: A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

A clinical trial evaluating a time-limited use of Ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdra…

CLINICAL_TRIALS withdrawal · 2025-03-07

Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas [Phase 1]

A Phase 1 study of CG-806 in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and non-Hodgkin's lymphomas ha…

CLINICAL_TRIALS withdrawal · 2025-02-28

Clinical Trial Update: Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation [Phase 1]

Phase 1 trial of ipilimumab, ibrutinib, and nivolumab for chronic lymphocytic leukemia and Richter transformation has been withdrawn.

CLINICAL_TRIALS withdrawal · 2024-10-15

Clinical Trial Update: Cardiotoxicities in Patients Receiving BTKi

A clinical trial evaluating cardiotoxicities in patients receiving Bruton's tyrosine kinase inhibitors has been withdrawn.

CLINICAL_TRIALS withdrawal · 2024-04-25

Clinical Trial Update: CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL [Phase 1]

A Phase 1 trial investigating CpG-STAT3 siRNA CAS3/SS3 with localized radiation for relapsed/refractory B-cell non-Hodgkin lymphomas has bee…

CLINICAL_TRIALS withdrawal · 2024-04-19

Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) [Phase 2, Phase 3]

Clinical trial ULTRA-V (Ublituximab with Umbralisib ± Venetoclax) in CLL/SLL has been terminated, with results posted.

CLINICAL_TRIALS withdrawal · 2024-04-02

Clinical Trial Update: A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies [Phase 3]

Phase 3 trial comparing lisocabtagene maraleucel vs investigator's choice in adult relapsed/refractory CLL/SLL has been withdrawn.

CLINICAL_TRIALS withdrawal · 2021-03-17

Clinical Trial Update: A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) [Phase 3]

Phase 3 trial BRAVURA evaluating duvelisib with rituximab and bendamustine versus placebo in indolent non-Hodgkin lymphoma was withdrawn.

CLINICAL_TRIALS withdrawal · 2017-12-02

Clinical Trial Update: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies [Phase 1, Phase 2]

A trial investigating T-regulatory cell and CD3-depleted double umbilical cord blood transplantation for hematologic malignancies has been w…

CLINICAL_TRIALS withdrawal · 2017-05-19

Clinical Trial Update: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]

The Phase 2 trial of Brentuximab Vedotin, Bendamustine, and Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdr…

CLINICAL_TRIALS withdrawal · 2017-04-05

Clinical Trial Update: Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation [Phase 2]

This clinical trial update reports that the Phase 2 study of Sotrastaurin acetate for relapsed or refractory chronic lymphocytic leukemia, s…

CLINICAL_TRIALS withdrawal · 2016-07-26

Clinical Trial Update: A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor [Phase 1]

A Phase 1 study of the combination of duvelisib and venetoclax in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lym…

CLINICAL_TRIALS withdrawal · 2016-03-02

Clinical Trial Update: Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1]

Phase 1 trial of MT-3724 for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma has been withdrawn; no results are reported…

CLINICAL_TRIALS withdrawal · 2015-03-06

Clinical Trial Update: Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant [Phase 2]

Phase 2 trial of lenalidomide with or without rituximab in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma after au…

Top drugs studied for this disease